Pathophysiology, Genetics & Classification

Question	Answer
1. What is the precise chromosomal locus and gene name mutated in Duchenne Muscular Dystrophy?	The DMD gene is located on the short arm of the X chromosome at locus Xp21.2, making it one of the largest human genes spanning over 2.2 million base pairs.
2. What is the primary protein product encoded by the DMD gene and what is its normal physiological function?	It encodes dystrophin, a 427 kDa cytoskeletal sub-sarcolemmal protein that mechanically links the intracellular actin cytoskeleton to the extracellular matrix via the dystrophin-glycoprotein complex (DGC).
3. What proportion of DMD cases arise due to spontaneous de novo mutations rather than maternal inheritance?	Approximately one-third (33%) of all DMD cases are caused by new spontaneous germline mutations, while two-thirds are inherited from carrier mothers.
4. What are the three primary molecular mutation types responsible for disrupting the dystrophin reading frame in DMD?	1. Large deletions (60-65%), 2. Large duplications (5-10%), and 3. Small point mutations, micro-deletions, or small insertions (small mutations constituting about 25-30%).
5. Explain the genetic reading frame rule that differentiates Duchenne Muscular Dystrophy from the milder Becker Muscular Dystrophy (BMD)?	In DMD, mutations disrupt the open reading frame (frameshift mutations), resulting in a complete absence of functional dystrophin; in BMD, in-frame mutations produce a truncated, partially functional protein.
6. What constitutes the dystrophin-glycoprotein complex (DGC), and why is its disruption catastrophic to muscle fibers?	The DGC is a multi-protein assembly including dystroglycans, sarcoglycans, and syntrophins that stabilizes the sarcolemma; its absence leads to mechanical fragility, micro-tears during contraction, and unregulated calcium influx.
7. What is the downstream cellular pathology triggered by chronic calcium overload in dystrophin-deficient myocytes?	Unchecked intracellular calcium influx hyperactivates calcium-dependent proteases (calpains) and phospholipases, causing mitochondrial permeability transition, myofibrillar degeneration, and eventual necrosis.
8. What histological hallmark replaces necrotic muscle fibers in the later stages of Duchenne Muscular Dystrophy?	Progressive fibro-fatty replacement (fibrosis mediated by TGF-beta and fatty infiltration), alongside variation in fiber size, internal nuclei, and regenerating basophilic fibers.
9. What role do immune-mediated inflammatory mechanisms play in the progression of DMD muscle damage?	Persistent muscle membrane damage triggers an influx of T-lymphocytes and macrophages, which release pro-inflammatory cytokines that exacerbate tissue injury and promote fibrogenesis.
10. Why are skeletal muscles predominantly affected while smooth muscle is largely spared in classic DMD?	Smooth muscle expresses distinct isoforms of dystrophin and components of the DGC (such as specific isoforms regulated by alternative promoters) that compensate for structural stresses.
11. How does the absence of dystrophin in cardiac muscle manifest structurally and pathologically over time?	It leads to X-linked dilated cardiomyopathy, characterized by progressive myocardial fibrosis involving the inferolateral left ventricular wall, interstitial edema, and eventual heart failure.
12. What functional classification system or staging is widely utilized to track the clinical progression of ambulation in DMD?	The 10-stage Brooke and Vignos functional rating scales are standard clinical tools used to grade lower extremity (Vignos) and upper extremity (Brooke) functional impairment.
13. What are the major phenotypic clinical tiers within the dystrophinopathy spectrum?	1. Duchenne Muscular Dystrophy (severe, non-ambulant by early teens), 2. Becker Muscular Dystrophy (milder, longer survival), and 3. X-linked dilated cardiomyopathy without significant skeletal myopathy.
14. What specific domain of the dystrophin protein anchors it to the actin cytoskeleton?	The N-terminal actin-binding domain of dystrophin binds tightly to F-actin, providing the critical mechanical anchor to the intracellular framework.
15. What is the function of the cysteine-rich C-terminal domain of dystrophin?	It binds directly to beta-dystroglycan, anchoring the entire DGC complex across the cell membrane to the extracellular matrix protein laminin-2.
16. VIVA TRAP: Can female carriers of the DMD gene mutation present with a full-blown Duchenne phenotype?	YES. Manifesting female carriers can develop severe DMD symptoms due to extreme skewed X-chromosome inactivation, Turner syndrome (45,X), or balanced X-autosome translocations involving the Xp21 locus.
17. Why does the vast majority of deletions cluster around specific "hotspots" within the DMD gene?	Hotspots occur predominantly around exons 45-55 (central rod domain) and exons 2-20 (N-terminal domain) due to high local density of repetitive intronic sequences prone to unequal crossing over during meiosis.
18. VIVA TRAP: Does the absolute quantity of residual truncated dystrophin directly correlate with clinical severity in all dystrophinopathy patients?	NO. While in-frame mutations generally produce milder BMD phenotypes, the functional capacity is also influenced by the specific location of the deleted domain, the presence of binding sites, and modifying genetic loci like SPP1 or LTBP4.
19. What is the primary pathomechanism behind central nervous system (CNS) involvement and cognitive impairment in a subset of DMD patients?	The loss of specific full-length and shorter central nervous system dystrophin isoforms (Dp140 and Dp71) expressed in the brain leads to alterations in synaptic plasticity, neuronal migration, and GABAergic receptor clustering.

Clinical History & Bedside Evaluation

Question	Answer
1. What is the typical age range at which parents first notice clinical symptoms in a child with Duchenne Muscular Dystrophy?	Symptoms are typically noticed between 2 to 3 years of age, often when the child exhibits delayed independent walking, frequent falls, or difficulty climbing stairs.
2. What are the earliest reported motor milestones that raise suspicion of proximal weakness in a toddler subsequently diagnosed with DMD?	Parents frequently report delayed independent ambulation (often past 18 months), waddling gait, difficulty rising from the floor, and an inability to run or jump normally.
3. How does the chronological progression of motor weakness typically unfold from early childhood to adolescence in DMD?	Weakness follows a predictable proximodistal gradient, beginning in the pelvic girdle and lower limbs, progressing to the shoulder girdle and upper limbs, leading to loss of ambulation by 10 to 12 years.
4. What specific historical detail regarding developmental milestones must be explicitly elicited during the neurological history of a suspected DMD case?	A detailed retrospective timeline of gross motor milestones must be captured, specifically noting the exact age of independent walking and whether the child ever ran with a normal pattern.
5. What is Gowers sign, and how do parents classically describe this maneuver in a child presenting with proximal lower limb weakness?	Gowers sign reflects proximal hip and thigh weakness; parents describe the child "walking up their own legs" with their hands to achieve an upright posture from a squatting position.
6. How does calf hypertrophy typically present in the clinical history, and why do parents often misinterpret this physical finding?	Parents often mistake prominent calf muscles as a sign of athletic strength or robust health, unaware that the bulk represents pathological pseudohypertrophy due to fibro-fatty replacement.
7. What specific nocturnal or morning respiratory history should be actively screened for in an older, non-ambulatory child with advanced DMD?	The examiner must screen for symptoms of nocturnal hypoventilation, including morning headaches, daytime somnolence, unrefreshing sleep, vivid nightmares, and recurrent nocturnal awakenings.
8. What gastrointestinal symptoms commonly arise in the later stages of DMD, and what is their underlying pathophysiological basis?	Dysphagia, frequent choking episodes, and severe chronic constipation frequently develop due to progressive smooth muscle and pharyngeal muscle dysfunction alongside prolonged immobility.
9. What specific family history pedigree details must be constructed when evaluating a suspected X-linked recessive muscular dystrophy?	A detailed three-generation pedigree must trace maternal uncles, male cousins on the maternal side who had similar motor delays or early deaths, and a history of miscarriage or unexplained male infant mortality.
10. Can a completely negative family history rule out Duchenne Muscular Dystrophy in a clinically suspected male child?	NO. Approximately one-third of all DMD cases represent sporadic de novo mutations arising spontaneously during maternal gametogenesis.
11. What critical dietary and nutritional history must be reviewed in a growing child with progressive DMD?	Dietary history must evaluate caloric intake versus declining energy expenditure to prevent rapid obesity, calcium and vitamin D intake for bone health, and adequate fluid and fiber intake to combat severe constipation.
12. What early behavioral or neurodevelopmental history is frequently uncovered in children with DMD prior to or alongside motor symptoms?	A history of delayed speech and language development, learning disabilities, attention deficit hyperactivity disorder (ADHD), or autism spectrum traits is notably prevalent due to brain-specific dystrophin isoform loss.
13. What differential diagnostic red flags in the perinatal and early infancy history would point away from DMD toward a congenital myopathy?	A history of severe neonatal hypotonia (floppy infant syndrome), arthrogryposis multiplex congenita, facial diplegia, or feeding difficulties in the first weeks of life strongly points to congenital myopathies rather than classic DMD.
14. What key historical feature helps differentiate Duchenne Muscular Dystrophy from spinal muscular atrophy (SMA) type II during bedside evaluation?	A history of steady, relentless motor deterioration with pseudohypertrophic calves strongly favors DMD, whereas SMA typically features areflexic proximal weakness with tongue fasciculations and a more static or slowly progressive course.
15. How do parents typically describe the evolution of the child's gait pattern during the ambulatory phase of the disease?	Parents report a progressively wide-based, waddling (myopathic/Trendelenburg) gait with compensatory lumbar lordosis that worsens when the child attempts to run or hurry.
16. What specific historical inquiry must be made regarding orthopedic complications in an adolescent DMD patient?	Clinicians must ask about the rapid onset of spinal curvature changes, back pain, and joint contractures affecting the ankles (heel cord tightening) and knees.
17. VIVA TRAP: Does the presence of normal early motor milestones up to 12 months definitively exclude the diagnosis of Duchenne Muscular Dystrophy?	NO. Most children with DMD achieve independent walking within the normal age window (often by 12 to 14 months) before manifesting overt proximal weakness and gait abnormalities in the second or third year of life.
18. What predisposing environmental or activity-related risk factors accelerate functional decline in a newly diagnosed DMD child?	Strenuous eccentric muscle exercises, prolonged immobilization following minor trauma or orthopedic surgery, and excessive weight gain significantly accelerate functional loss.
19. What historical clues during the adolescent review of systems would indicate the onset of acute pulmonary compromise?	A history of weak, ineffective cough, recurrent lower respiratory tract infections, and difficulty clearing upper airway secretions indicates declining respiratory reserve requiring proactive pulmonary management.

Physical Examination & Bedside Signs

Question	Answer
1. What is the standard anthropometric pattern seen in advanced Duchenne Muscular Dystrophy, and why does body composition shift significantly?	1. Severe muscle wasting and limb-girdle hypotrophy coupled with relative truncal and facial adiposity. 2. Driven by chronic glucocorticoid therapy combined with complete loss of ambulation and reduced caloric expenditure.
2. What specific inspection finding is classically observed in the calves of a child with Duchenne Muscular Dystrophy?	1. Pseudohypertrophy, where the gastrocnemius and soleus muscles appear disproportionately bulky and firm. 2. On inspection, this bulk is often accompanied by an abnormally firm contour due to replacement of contractile tissue by fibrofatty infiltration.
3. How is Gowers maneuver systematically elicited at the bedside, and what muscle groups are primarily failing to allow this compensatory pattern?	1. The child is asked to rise from a lying-down floor position; they roll to the prone/all-fours position, push up their knees, and "walk" their hands up their thighs. 2. This reflects severe weakness of the proximal hip extensors (gluteus maximus) and knee extensors (quadriceps femoris).
4. What is Gowers sign grading, and how does a grade 2 Gowers maneuver manifest clinically?	1. Grading assesses the degree of upper limb and trunk compensation required to rise from the floor. 2. Grade 2 specifically requires the child to place their hands on their knees and subsequently on their thighs (climbing up their own legs) to achieve an upright posture.
5. What specific gait abnormality is observed on inspection when a child with DMD walks during the ambulatory phase?	1. A characteristic waddling (myopathic) gait characterized by bilateral hip drop (Trendelenburg sign) during the swing phase. 2. This is caused by early weakness of the gluteus medius and minimus muscles stabilizing the pelvis.
6. How does the lordotic posture manifest upon standing inspection in a child with early-to-moderate DMD?	1. Pronounced lumbar hyperlordosis. 2. This develops as a compensatory mechanism to shift the body's center of gravity posterior to the hip joints, helping maintain upright balance against failing hip extensors.
7. What specific finding is elicited during palpation of the calf muscles in established DMD compared to normal muscle?	1. Palpation reveals a woody, firm, or doughy consistency rather than the supple, elastic feel of healthy skeletal muscle. 2. This distinct consistency is due to extensive endomysial fibrosis and adipose tissue deposition.
8. What reflex finding is characteristic of the lower extremities during neurological examination in a school-aged child with DMD?	1. Hyporeflexia or eventual complete abolition of the knee and ankle jerks. 2. Deep tendon reflexes progressively disappear in parallel with the loss of functional muscle mass and structural integrity of the motor unit.
9. What pattern of muscle weakness distribution is classically documented on manual muscle testing (MMT) in DMD?	1. A remarkably symmetrical, proximal-greater-than-distal weakness pattern. 2. Lower extremities are affected significantly earlier and more severely than upper extremities, with pelvic girdle muscles failing before shoulder girdle muscles.
10. What specific scapular abnormality becomes apparent upon inspecting the upper back and shoulders of an older ambulatory or early non-ambulatory DMD child?	1. Scapular winging. 2. Caused by weakness of the serratus anterior and trapezius muscles, leading to failure of scapular fixation against the thoracic cage during arm elevation.
11. What precise auscultatory and clinical inspection signs indicate the development of cardiomyopathy in a late-stage DMD patient?	1. Inspection may reveal a displaced apex beat and signs of systemic venous congestion (raised jugular venous pressure, peripheral edema). 2. Auscultation frequently detects a gallop rhythm (S3 or S4), systolic murmurs of mitral regurgitation, and distant heart sounds due to myocardial fibrosis.
12. How does ankle joint inspection and passive range of motion testing reveal early contracture formation in DMD?	1. Inspection often shows early equinovarus positioning, and passive dorsiflexion of the ankle is severely restricted. 2. This occurs due to early relative tightness and fibrosis of the gastrocnemius-soleus complex compared to the weaker anterior compartment muscles.
13. What is the clinical significance of eliciting a positive Trendelenburg sign during the single-leg stance test in early DMD?	1. When the child stands on one leg, the pelvis drops on the unsupported (swing) side instead of rising. 2. It confirms significant weakness of the contralateral gluteus medius muscle, which is an early hallmark of proximal pelvic girdle involvement.
14. What physical sign indicates the transition from the ambulatory to the non-ambulatory phase during bedside functional evaluation?	1. Inability to climb stairs or rise from a standard chair without substantial external assistance or upper limb bracing. 2. The child completely loses the capacity to maintain unassisted upright bipedal locomotion, typically occurring around 9 to 12 years of age.
15. What physical sign on chest wall inspection alerts the clinician to impending restrictive ventilatory failure in an adolescent DMD patient?	1. Paradoxical inward abdominal movement during inspiration and prominent use of accessory muscles of respiration (sternocleidomastoids). 2. This reflects severe diaphragmatic and intercostal muscle weakness leading to microatelectasis and progressive chest wall deformity.
16. VIVA TRAP: Does the presence of preserved deep tendon reflexes in the lower limbs completely rule out Duchenne Muscular Dystrophy in a 5-year-old child?	1. NO. 2. Deep tendon reflexes may be preserved or only sluggishly diminished in the early ambulatory stages of DMD when muscle bulk and stretch receptors are still partially functional.
17. What specific spinal inspection finding invariably develops in non-ambulatory DMD patients who are not aggressively managed with seating systems or surgery?	1. Progressive, severe progressive neuromuscular scoliosis. 2. This results from asymmetric truncal muscle weakness, pelvic obliquity, and gravity acting on a poorly supported spinal column.
18. What bedside maneuver is used to evaluate upper extremity proximal weakness equivalent to Gowers sign in the arms?	1. Asking the child to lift heavy objects overhead or observing inability to perform the "arm-raising" test against gravity. 2. This highlights early shoulder girdle and deltoid/pectoralis weakness (manifesting as difficulty bringing arms above the horizontal plane).
19. VIVA TRAP: Can calf pseudohypertrophy be reliably differentiated from true muscular hypertrophy by visual inspection alone?	1. NO. 2. Visual inspection is deceptive; true hypertrophy looks identical to pseudohypertrophy, and definitive differentiation requires physical palpation (woody/firm consistency) combined with serum CK levels and genetic testing.

Diagnostic Criteria & Investigations

Question	Answer
1. How do serum CK levels change as the disease progresses from early childhood to the late non-ambulatory stage of DMD?	Serum CK levels progressively decline over time as functional muscle mass is replaced by fibro-fatty tissue, eventually dropping to near-normal levels in severely wasted, late-stage non-ambulatory adolescents.
2. What is the historical role of skeletal muscle biopsy in modern diagnostic algorithms for DMD, and when is it still indicated?	1. Muscle biopsy with immunohistochemistry (IHC) or Western blot for dystrophin protein expression was previously the diagnostic gold standard. 2. It is now reserved for cases where genetic testing via MLPA and NGS fails to identify a mutation despite classic clinical and laboratory features.
3. What specific histological findings on a muscle biopsy support the diagnosis of a dystrophinopathy?	1. Marked variation in muscle fiber size with prominent atrophic and hypertrophic fibers. 2. Increased internal nuclei, foci of fiber necrosis and phagocytosis, and extensive endomysial fibro-fatty replacement.
4. What immunohistochemical staining pattern of dystrophin is characteristic of classic Duchenne Muscular Dystrophy versus Becker Muscular Dystrophy?	1. In DMD, immunohistochemistry shows complete absence (or less than 3%) of sarcolemmal staining for dystrophin. 2. In Becker MD, dystrophin staining is typically patchy, reduced in intensity, or of abnormal molecular weight on Western blot.
5. What role do electromyography (EMG) and nerve conduction studies (NCS) play in the routine diagnostic workup of DMD?	1. EMG typically demonstrates a myopathic motor unit action potential (MUAP) pattern with short duration, low amplitude, and early recruitment, alongside fibrillations and positive sharp waves. 2. NCS are completely normal, confirming a primary muscle pathology without peripheral nerve involvement.
6. What are the diagnostic implications of elevated transaminases (AST and ALT) in an asymptomatic toddler presenting for routine evaluation?	1. SGOT/AST and SGPT/ALT are heavily expressed in skeletal muscle tissue as well as the liver. 2. Isolated elevations in transaminases with normal bilirubin and alkaline phosphatase frequently lead pediatricians to misdiagnose liver disease before recognizing underlying muscular dystrophy.
7. What cardiac diagnostic investigations are mandatory at the time of initial diagnosis of Duchenne Muscular Dystrophy?	1. Baseline 12-lead electrocardiogram (ECG) to look for deep Q waves in lateral leads, right bundle branch block, or sinus tachycardia. 2. Transthoracic echocardiography or cardiac MRI to establish baseline left ventricular ejection fraction and global longitudinal strain.
8. What pulmonary function tests (PFTs) are prioritized during the serial diagnostic monitoring of a growing DMD patient?	1. Forced vital capacity (FVC) and peak cough flow (PCF) are essential parameters. 2. As the disease advances, FVC transitions from a normal restrictive pattern to progressive decline, predicting impending ventilatory failure.
9. What screening diagnostic test is recommended for female family members to determine carrier status in an affected DMD pedigree?	1. Serum creatine kinase estimation, which is elevated in approximately 50% of heterozygous female carriers. 2. Definitive carrier testing requires genetic analysis using MLPA or targeted mutation assays to identify the specific familial deletion or point mutation.
10. What role does prenatal diagnosis play in families with a previously affected child, and at what gestational age is it performed?	1. Prenatal diagnosis is offered via chorionic villus sampling (CVS) around 10 to 12 weeks of gestation or amniocentesis around 15 to 18 weeks. 2. It requires prior identification of the specific index case mutation to perform targeted familial mutation testing.
11. What radiological finding is classically demonstrated on magnetic resonance imaging (MRI) of the thighs in early-to-moderate DMD?	1. T1-weighted MRI sequences demonstrate symmetrical, diffuse fibro-fatty replacement starting characteristically in the gluteus maximus, vastus lateralis, and adductor magnus muscles. 2. The rectus femoris, gracilis, and sartorius muscles are characteristically spared until much later stages of the disease.
12. VIVA TRAP: Can a normal serum creatine kinase (CK) level rule out Duchenne Muscular Dystrophy in a 6-year-old boy presenting with proximal weakness and Gowers sign?	NO. While a normal CK makes DMD highly unlikely, late-stage non-ambulatory patients with severe muscle wasting and extensive fibro-fatty replacement can have near-normal or baseline serum CK levels.
13. What specific ECG abnormality is considered a classic early diagnostic marker of myocardial involvement in DMD?	Tall R waves in lead V1, deep Q waves in the inferior (II, III, aVF) and lateral (I, aVL, V5, V6) leads, and an increased R/S ratio in V1 reflecting posterobasal fibrosis.
14. What diagnostic blood tests must be routinely monitored alongside serum CK in a newly diagnosed DMD patient before starting corticosteroid therapy?	Baseline complete blood count, renal function tests, fasting blood glucose, vitamin D levels, and hepatitis/varicella/tuberculosis screening due to the immunosuppressive and metabolic side effects of long-term steroids.
15. VIVA TRAP: Is a muscle biopsy mandatory prior to initiating genetic testing if multiplex ligation-dependent probe amplification (MLPA) is readily available?	NEVER. Current international and national standards of care dictate that genetic testing (MLPA and NGS) is the primary first-line diagnostic modality, making invasive muscle biopsy unnecessary in the vast majority of cases.
16. What diagnostic clues on routine hematology panels help differentiate Duchenne Muscular Dystrophy from acquired inflammatory myopathies like dermatomyositis?	1. DMD shows markedly higher serum CK levels, an absence of inflammatory infiltrates on genetic/biopsy profiles, and characteristically lacks extramuscular features like heliotrope rashes or Gottron papules. 2. Inflammatory myopathies present with positive autoantibodies (e.g., anti-Jo1, anti-Mi2) and prominent perivascular inflammation on histology.
17. What specialized polysomnography (PSG) or nocturnal oximetry diagnostic study is indicated when an adolescent with DMD develops nocturnal hypoventilation symptoms?	Attended overnight polysomnography or nocturnal pulse oximetry coupled capnography to document nocturnal hypercapnia, obstructive/central apneas, and oxygen desaturations, guiding the timely initiation of non-invasive positive pressure ventilation (NIPPV).

Evidence-Based Management & Pharmacotherapy

Question	Answer
1. What is the standard first-line pharmacological therapy recommended to alter the natural history and preserve motor function in Duchenne Muscular Dystrophy?	1. Corticosteroids (Prednisolone or Deflazacort) are the cornerstone of disease-modifying therapy. 2. They prolong ambulation, preserve respiratory and cardiac function, and reduce the incidence of scoliosis. 3. Therapy is typically initiated when the child is between 4 and 6 years of age, or during the plateau phase of motor development.
2. What is the recommended starting dosage for Deflazacort when chosen as the corticosteroid of choice for Duchenne Muscular Dystrophy, and what is its conversion factor relative to prednisolone?	1. Deflazacort is initiated at a dose of 0.9 mg/kg/day orally. 2. The equivalent anti-inflammatory and therapeutic potency ratio compared to prednisolone is roughly 1.2 to 1.5 to 1 (i.e., 0.9 mg of deflazacort is equivalent to 0.75 mg of prednisolone). 3. Deflazacort is often preferred over prednisolone by many clinicians due to a potentially lower incidence of severe weight gain.
3. What are the key baseline investigations and vaccinations required before initiating systemic corticosteroid therapy in a child with DMD?	1. Complete baseline screening must include assessing growth parameters, blood pressure, fasting blood glucose or HbA1c, lipid profile, and a baseline DXA scan or spinal/long bone radiographs. 2. Infectious screening for latent tuberculosis (Mantoux or IGRA) and hepatitis B/C must be performed. 3. Live attenuated vaccines must be updated prior to starting immunosuppressive corticosteroid regimens.
4. What pharmacological agents are recommended for cardiac protection and management of cardiomyopathy when it develops in DMD patients?	1. ACE inhibitors (such as Enalapril or Lisinopril) or Angiotensin Receptor Blockers (ARBs) are initiated as first-line cardioprotective agents. 2. Beta-blockers (such as Carvedilol) are added if left ventricular dysfunction progresses. 3. These agents should ideally be started by 10 years of age or earlier if cardiac imaging shows subclinical myocardial strain abnormalities, even before clinical symptoms appear.
5. What is the mechanism of action of Ataluren (Translarna), and which specific subset of DMD patients is eligible for its use?	1. Ataluren is a nonsense mutation readthrough drug that enables ribosomal readthrough of premature stop codons (nonsense mutations) in the mRNA, allowing the synthesis of full-length, functional dystrophin. 2. It is indicated for ambulatory patients aged 2 years and older with nonsense mutation-type DMD (nmDMD).
6. What are the major adverse drug reactions of chronic systemic corticosteroid therapy that mandate active surveillance during follow-up?	1. Excessive weight gain and Cushingoid facies. 2. Linear growth retardation and delayed puberty. 3. Decreased bone mineral density leading to symptomatic vertebral compression fractures. 4. Behavioral changes (mood lability, aggression), cataracts, and impaired glucose tolerance.
7. What routine monitoring schedule and blood investigations are mandatory for a patient on long-term daily corticosteroid therapy for DMD?	1. Clinical evaluation of weight, height, blood pressure, and pubertal staging every 3 to 6 months. 2. Annual fasting blood glucose or HbA1c and lipid profile. 3. Annual or bi-annual assessment of bone health using spine radiographs or DXA scans to monitor for asymptomatic vertebral fractures.
8. What bone-protective pharmacological agents are indicated when a DMD child on chronic corticosteroids develops osteopenia or vertebral fractures?	1. Oral or intravenous bisphosphonates (such as zoledronic acid or pamidronate) are the primary pharmacological agents used to treat established osteoporosis and painful vertebral fractures. 2. Adequate daily supplementation of elemental calcium and vitamin D3 must be ensured concurrently in all patients on corticosteroids.
9. What is the stepwise pharmacological and non-pharmacological approach for managing acute nocturnal hypoventilation in an adolescent with advanced DMD?	1. Non-pharmacological management is primary, consisting of the early introduction of non-invasive positive pressure ventilation (NIPPV) via nasal or full-face mask (such as BiPAP). 2. Cough assist devices (mechanical insufflation-exsufflation) are introduced to clear retained airway secretions and prevent atelectasis. 3. Routine use of respiratory depressants (sedatives, opioids) is strictly avoided.
10. What pharmacological management is indicated for gastrointestinal complications such as severe chronic constipation or gastroesophageal reflux in non-ambulatory DMD?	1. Osmotic laxatives (such as polyethylene glycol or lactulose) combined with adequate hydration and fiber intake for management of slow-transit constipation caused by smooth muscle involvement and physical immobility. 2. Proton pump inhibitors (such as omeprazole or pantoprazole) are indicated for symptomatic gastroesophageal reflux disease, which is common due to delayed gastric emptying and altered thoraco-abdominal pressures.
11. What perioperative pharmacological considerations and anesthetic precautions are vital during surgical interventions in children with DMD?	1. Inhalational volatile anesthetic agents (such as halothane or isoflurane) and depolarizing muscle relaxants (such as succinylcholine) are strictly contraindicated because they trigger catastrophic rhabdomyolysis, hyperkalemia, and malignant hyperthermia-like reactions. 2. Total intravenous anesthesia (TIVA) or non-depolarizing neuromuscular blockers under careful train-of-four monitoring must be utilized.
12. What specific multidisciplinary surveillance clinics and subspecialty reviews are recommended as part of the long-term management protocol for DMD?	1. Regular surveillance requires coordinated multidisciplinary care involving pediatric neurology, cardiology (annual ECG and echocardiogram/MRI), pulmonology (serial PFTs and sleep studies), physical and occupational therapy, orthopedics, endocrinology, and nutrition/dietetics.
13. What is the recommended pharmacological strategy for managing corticosteroid-induced behavioral side effects or severe emotional lability in young children with DMD?	1. Behavioral strategies and structured psychological support are the first line of intervention. 2. If pharmacological intervention is necessary due to severe disruptive aggression or profound mood dysregulation, short-acting psychotropic medications or adjusting the corticosteroid dosing schedule (e.g., shifting from daily to weekend-only dosing) under specialist psychiatric guidance can be considered.
14. VIVA TRAP: Can systemic corticosteroids be abruptly stopped in a 10-year-old child with DMD who has developed severe cushingoid features and excessive weight gain?	NO. Abrupt cessation of systemic corticosteroids can precipitate life-threatening acute adrenal crisis due to secondary hypothalamic-pituitary-adrenal axis suppression; the dose must be slowly and systematically tapered under strict medical supervision.
15. What specific cardiac monitoring schedule is mandated by international consensus guidelines for asymptomatic patients diagnosed with Duchenne Muscular Dystrophy?	1. Baseline cardiac evaluation with a standard 12-lead ECG and echocardiography (with speckle-tracking strain analysis if available) is mandatory at the time of diagnosis or by 6 years of age. 2. Monitoring must be performed at least annually up to 10 years of age, and every 6 months thereafter, or earlier if cardiac symptoms or abnormal strain patterns emerge.
16. What physical therapy interventions and daily stretching regimens form an essential component of non-pharmacological management to delay contracture formation?	1. Daily gentle, passive stretching exercises of major muscle groups—specifically the heel cords (gastrocnemius-soleus complex), tensor fascia lata, and hip flexors—performed by trained family members. 2. Use of daytime or night splints and ankle-foot orthoses (AFOs) during the late ambulatory and early non-ambulatory phases to maintain range of motion.
17. VIVA TRAP: Is routine chest physiotherapy and mechanical cough-assist device use indicated in an asymptomatic 5-year-old ambulatory child with genetically confirmed DMD?	NO. Mechanical insufflation-exsufflation devices and aggressive chest physiotherapy are reserved for non-ambulatory patients with a weak cough reflex and declining forced vital capacity, whereas an asymptomatic 5-year-old ambulatory child has preserved bulbar and respiratory muscle function.

High-Yield VIVA TRAPs & Examiner Pitfalls

Question	Answer
1. VIVA TRAP: Can succinylcholine or volatile halogenated anesthetic agents be safely administered during general anesthesia for a routine orthopedic tendon release in an undiagnosed or diagnosed DMD patient?	NEVER. Succinylcholine and volatile anesthetic agents (like halothane or isoflurane) are absolutely contraindicated as they trigger life-threatening acute rhabdomyolysis, severe hyperkalemia, and malignant hyperthermia-like reactions in dystrophinopathy patients.
2. VIVA TRAP: Should high-intensity, maximal-resistance weight training or eccentric muscle strengthening be prescribed to a 7-year-old ambulatory boy with Duchenne Muscular Dystrophy to build muscle bulk?	NEVER. High-intensity resistance exercises and eccentric contractions cause excessive mechanical microtrauma to fragile, dystrophin-deficient sarcolemma membranes, accelerating muscle fiber degeneration and necrosis.
3. VIVA TRAP: Is routine prescription of high-dose Vitamin D and calcium supplementation optional when initiating daily systemic corticosteroid therapy in a newly diagnosed toddler with DMD?	NO. Prophylactic calcium and Vitamin D supplementation is mandatory from day one of starting systemic corticosteroids to mitigate rapid bone mineral density loss and prevent fragility fractures.
4. VIVA TRAP: Can live attenuated vaccines (such as MMR or Varicella) be administered to a DMD patient who has been established on daily high-dose oral corticosteroid therapy for over 6 months?	NEVER. Live attenuated vaccines are strictly contraindicated in patients receiving immunosuppressive doses of systemic corticosteroids due to the severe risk of disseminated, life-threatening vaccine-strain infection.
5. VIVA TRAP: Is a normal echocardiogram at 6 years of age sufficient to permanently rule out the future development of cardiomyopathy in a growing boy with DMD?	NO. Cardiac involvement is progressive and age-dependent; all DMD patients develop cardiomyopathy by late adolescence, necessitating serial cardiac screening every 1 to 2 years even with normal baseline findings.
6. VIVA TRAP: Should passive stretching exercises of the heel cords and Achilles tendons be abruptly abandoned if the child complains of mild discomfort during physical therapy?	NO. Stopping stretching regimens leads to rapid, irreversible joint contractures; gentle, consistent daily passive stretching by trained caregivers must be maintained, adjusting the intensity rather than discontinuing it.
7. VIVA TRAP: Can angiotensin-converting enzyme (ACE) inhibitors or beta-blockers be withheld in an asymptomatic 12-year-old with DMD until overt left ventricular systolic dysfunction or heart failure symptoms appear?	NEVER. Current consensus guidelines recommend initiating cardioprotective therapy with ACE inhibitors (or ARBs) by 10 years of age, or earlier if indicated, regardless of symptoms, to significantly delay the onset of myocardial fibrosis and failure.
8. VIVA TRAP: Is it acceptable to permit competitive contact sports or long-distance endurance running for an early ambulatory 5-year-old child who only shows mild motor clumsiness?	NEVER. Strenuous, high-impact, and competitive endurance sports accelerate muscle damage in dystrophin-deficient myofibers; low-impact recreational activities like swimming and gentle cycling should be encouraged instead.
9. VIVA TRAP: Should nightly non-invasive positive pressure ventilation (NIPPV) be delayed in an adolescent with DMD until he develops daytime hypercapnia and overt respiratory failure?	NO. Prophylactic initiation of nocturnal NIPPV is indicated as soon as nocturnal hypoventilation or significant nocturnal oxygen desaturations are documented on sleep studies, long before daytime hypercapnia sets in.
10. VIVA TRAP: Is surgical correction of severe spinal scoliosis contraindicated in a non-ambulatory 15-year-old teenager with moderately impaired pulmonary function (FVC < 40%)?	NO. Spinal fusion surgery is frequently indicated to stabilize progressive scoliosis, protect remaining pulmonary function, improve sitting balance, and enhance quality of life, provided rigorous perioperative cardiopulmonary optimization is performed.
11. VIVA TRAP: Should annual influenza and pneumococcal vaccinations be omitted in asymptomatic ambulatory children with DMD because they have normal baseline respiratory function?	NEVER. Annual influenza vaccination and age-appropriate pneumococcal immunizations are mandatory for all DMD patients to prevent severe lower respiratory tract infections that can precipitate rapid, irreversible respiratory decompensation.
12. VIVA TRAP: Can genetic counseling and carrier testing be omitted for maternal relatives if the index DMD case represents an apparent isolated sporadic mutation in the family?	NO. Approximately one-third of DMD cases arise from de novo maternal germline or somatic mosaicism; comprehensive carrier screening and genetic counseling must be offered to all at-risk female relatives.
13. VIVA TRAP: Can routine screening for asymptomatic left ventricular dysfunction be safely delayed until a teenager with DMD reaches 15 years of age?	NEVER. International guidelines mandate baseline cardiac evaluation at the time of diagnosis (or by 6 years of age) and comprehensive annual screening thereafter, as subclinical myocardial fibrosis can begin much earlier in childhood.
14. VIVA TRAP: Is physical therapy alone sufficient to prevent lower extremity contractures without the routine nighttime use of ankle-foot orthoses (AFOs) in non-ambulatory DMD?	NO. Nighttime ankle-foot orthoses or knee-ankle-foot orthoses are critical adjuncts to physical therapy to maintain optimal ankle dorsiflexion and delay severe lower limb contracture progression.
15. VIVA TRAP: Can cough assist devices (mechanical insufflation-exsufflation) be withheld in a non-ambulatory adolescent with DMD until he experiences a severe episode of aspiration pneumonia?	NEVER. Prophylactic mechanical insufflation-exsufflation devices must be prescribed and trained early upon the onset of a weak cough reflex to prevent recurrent mucous plugging, atelectasis, and acute respiratory failure.